Linda Cahill, President & CEO
Prior to co-founding Cell Biosciences, Linda was the chairman of the Beckman Laser Institute on the University of California, Irvine Campus. Linda has over 25 years of senior management experience in the pharmaceutical and life science industries. As Vice President with responsibilities for venture investing, business development and strategic planning at Johnson and Johnson, she had one of the highest venture returns in the industry. Her investments included J&J’s investment in Chiron that led to the commercialization of Hepatitis C diagnostics and growth factors for wound healing. Linda also initiated the acquisition of LifeScan Diagnostics at J&J. Before J&J, Linda was Director of Corporate Development at Merck, where she also held positions in finance and strategic planning. Linda holds an MBA from Columbia University.

Wilhelm G. Lachnit, Ph.D.,
Vice-President of Sales and Marketing
Will has over 20 years experience in pharma/biotech and life sciences. Will joined the company from Molecular Devices where he was most recently Director of Drug Discovery Sales and Support for North America. While there, he managed double digit growth in their large capital equipment. From 2002 to 2003, he held marketing and product development management positions overseeing the successful launch of the IonWorks^TM product line. Will joined Molecular Devices as Director of Business Development in 2000 where he was involved with the acquisition and integration of multiple acquisitions into the organization. Prior to that, he held research management and scientific positions at Roche and Syntex (acquired by Roche) where he pioneered the early adoption of automated cell-based assays. Will holds a Ph.D. in Pharmacology-Toxicology from the University of California, Davis.

^Top

Board of Directors

Linda Cahill, President & CEO
Prior to co-founding Cell Biosciences, Linda was the chairman of the Beckman Laser Institute on the University of California, Irvine Campus. Ms. Cahill has over 25 years of senior management experience in the pharmaceutical and life science industries. As Vice President with responsibilities for venture investing, business development and strategic planning at Johnson and Johnson, she had one of the highest venture returns in the industry. Her investments included J&J’s investment in Chiron that led to the commercialization of Hepatitis C diagnostics and growth factors for wound healing. Linda also initiated the acquisition of LifeScan Diagnostics at J&J. Before J&J, Linda was Director of Corporate Development at Merck, where she also held positions in finance and strategic planning. Linda holds an MBA from Columbia University.

A. Blaine Bowman, Lead Director
Mr. Bowman was most recently the President and Chief Executive Officer of Dionex Corporation (NASDAQ: DNEX), a leading developer and manufacturer of laboratory and process analytical systems and related products. Mr. Bowman joined the company in 1977. Under his leadership, Dionex grew from $1 million in sales to over $180 million and is widely respected for its innovative products and solid growth. Earlier, he was a management consultant with McKinsey and Company and a product engineer at Motorola Semiconductor Products Division. Mr. Bowman holds a B.S. Degree in Physics from Brigham Young University and a MBA from Stanford University Graduate School of Business. Additionally, Mr. Bowman has served on the Board of Directors of Molecular Devices Corporation since 1992.

Jim Blair, Domain Associates (www.domainvc.com)
Mr. Blair has been a General Partner of Domain Associates since its founding in 1985. He has over thirty years experience with venture and emerging growth companies. In the course of this experience, he has been involved with the creation and successful development as a board member of over forty life science ventures including Amgen, Amylin Pharmaceuticals, Applied Biosystems, Aurora Biosciences, Dura Pharmaceuticals, Sicor, and Molecular Dynamics. Mr. Blair is presently an advisor to the Department of Molecular Biology at Princeton University, an Advisor to the Department of BioEngineering at the University of Pennsylvania, and he also serves on the Board of Directors of the Prostate Cancer Foundation.

Jim Woody, Ph.D., Latterell Venture Partners (www.lvpcapital.com)
Dr. Woody brings more than 25 years of biomedical research and management experience to LVP. Dr. Woody was formerly President of Roche Bioscience in Palo Alto, CA where he had responsibility for all bioscience research and development, ranging from genetics and genomics to clinical development. Previously, Dr. Woody served as Chief Scientific Officer and Senior Vice President of R & D for Centocor, where he was responsible for the discovery and early clinical development of antibody and peptide-based therapeutic products. While at Centocor, Dr. Woody developed Remicade^®, the first of the TNF inhibitor biologics, as well as ReoPro^®, a novel platelet blocking drug used in conjunction with angioplasty. Prior to Centocor, Dr. Woody served as Commanding Officer and Director, US Naval Medical Research and Development Command in Bethesda Maryland. In that role, he was responsible for a wide range of medical research and development activities ranging from transplantation research to infectious diseases. He was responsible for the surveillance, detection and therapy for all Biologic Warfare Agents and Infectious Diseases in the first Gulf War, and was awarded the US Navy Legion of Merit for his service. Dr. Woody holds an M.D. from Loma Linda University, trained in Pediatric Immunology at Duke University and Children’s Hospital in Boston (Harvard), and holds a Ph.D. in Immunology from the University of London, England.

David L. Barker, PhD
Dr. David L. Barker serves on the Boards of Directors of Cell Biosciences, Excellin Life Sciences Inc., and Microchip Biotechnologies, Inc. From 2000 through 2006 he was Vice President and Chief Scientific Officer at Illumina, Inc., in San Diego, California, a leading developer of genomic analysis systems. Dr. Barker served from 1998 to 2000 as Vice President and Chief Science Advisor at Amersham Biosciences, now part of General Electric. From 1988 to 1998, Dr. Barker held senior positions, including Vice President of Research and Business Development, at Molecular Dynamics, Inc., until the acquisition of Molecular Dynamics by Amersham.

In his academic career, Dr. Barker conducted interdisciplinary research in neurobiology as a postdoctoral fellow at Harvard Medical School, Assistant Professor at the University of Oregon and Associate Professor at Oregon State University. Dr. Barker holds a BS with honors in Chemistry from the California Institute of Technology and a PhD in Biochemistry from Brandeis University.

Julie Eskay-Eagle is the Co-Head of Health Care and Venture Capital Investments for The Wellcome Trust, which manages over $20 billion in assets. Her responsibilities include managing direct investments in 18 venture investments in the life sciences sector as well as relationships with leading health care venture funds and investments totaling over $300 million in health care-specific public equity funds. Prior to joining the Trust Ms. Eskay-Eagle was a Vice President with Lazard Freres in Health Care Investment Banking and a founding member of Lazard Technology Partners. Before joining Lazard, she was a Health Care Specialist with McKinsey & Co. in New York. Ms. Eskay-Eagle has a bachelor’s degree in Biomedical Ethics from Cornell University and an MBA from Columbia University. Ms. Eskay-Eagle is currently a director of Cell Biosciences, Sequoia Pharmaceuticals, Chroma Therapeutics and Amplimmune.

Jack Nielsen is Partner in Novo Ventures where he joined in 2001.

From 1990 to 2001 Mr. Nielsen held various positions in the Novo Nordisk business area which in 2000 became Novozymes A/S. The last four years before joining Novo Ventures he was deeply involved in designing the R&D strategy for the company's efforts in the Cereal Food area, resulting in the development and launch of novel recombinant lipase and amylase enzymes. Mr. Nielsen was previously involved in collaborations with Procter & Gamble, Danisco, and Quest International to identify new enzymes for the detergent and cereal food industry. He held positions in marketing and technical services in the textile and personal care area, and started his carrier in the field of large-scale manufacturing of enzymes. Mr. Nielsen serves on the boards of directors of Cell Biosciences, Inc., Protein Forest, Inc. and Reata Pharmaceuticals, Inc., and he is a former director of Panacos Pharmaceuticals, Inc., Nuevolution A/S, and CardioOptics, Inc.

Jack Nielsen obtained his MSc in 1990 from the Technical University of Denmark, and his Master in Management of Technology from the Center for Technology, Economics and Management in Copenhagen in 2000.

^Top

Scientific Advisory Board

Cell Biosciences enjoys the participation of a strong team of world-renown scientists in the field of cellular and molecular biology, immunology and medical research. These scientists have joined Cell Biosciences Scientific Advisory Board based on their collective interest in the development of new, enabling technology for cell signaling and protein research.

Stanley Falkow, Ph.D., Professor of Microbiology & Immunology Stanford, University School of Medicine
Dr. Falkow’s research focuses on the understanding of how bacterial agents cause infection and disease. His laboratory is recognized throughout the world for their observations related to molecular mechanisms of bacterial pathogenesis. Dr. Falkow was elected as a member of the National Academy of Sciences in 1984 and the Institute of Medicine in 1997. In 2003, Dr. Falkow received the National Academy’s Waksman Award in Microbiology, one of many past awards for his research efforts. Dr. Falkow served as Chairman of the Department of Medical Microbiology at Stanford from 1981 to 1985 and held past professorships at the University of Washington and Georgetown University Medical Schools. Dr. Falkow is also a past-President of the American Society for Microbiology. He received his B.S. degree from the University of Maine and his Ph.D. from Brown University.

Tony Hunter, Ph.D., Professor of Molecular & Cell Biology Salk Institute for Biological Studies
Dr. Hunter studies how cells regulate their growth and division, and how mutations in genes that regulate growth lead to cancer. His lab has made significant contributions in the area of signal transduction, how signals that stimulate or rein in growth are routed within a cell. In 1979, Dr. Hunter’s Lab discovered that phosphate can be attached to tyrosine residues in proteins. This seminal discovery opened the door to the study of tyrosine kinases in cell signaling and their role in cancer and other human diseases. Dr. Hunter was elected as a member of the National Academy of Sciences in 1998. Dr. Hunter has received numerous government, society and industry awards for his research over the past several years. Dr. Hunter holds bachelor’s and Ph.D. degrees with honors from the University of Cambridge.

Dean Felsher, M.D., Ph.D., Assistant Professor of Oncology & Pathology Stanford University School of Medicine
Dr. Felsher’s Lab investigates how genes related to cancer initiate and sustain tumors. Dr. Felsher has developed novel model systems to conditionally activate cancer genes in normal human and mouse cells in tissue culture or in specific tissues in transgenic mice. In particular Dr. Felsher has found new evidence of correlation of cancer activation and inactivation related to a proto-oncogene known as Myc. This work led to a land mark paper Nature Magazine in late 2004. Prior to Stanford, Dr. Felsher served on the faculty of the Division of Hematology-Oncology at UCSF, served fellowships at UCSF and the Hooper Foundation and was a resident at the Hospital of the University of Pennsylvania. Dr. Felsher holds a bachelor’s degree in Chemistry from the University of Chicago and a M.D.-Ph.D. degree in Molecular Biology from the UCLA School of Medicine.

Robert Kennedy, Ph.D., Professor of Chemistry & Pharmacology, University of Michigan
Dr. Kennedy’s research focuses on the development of nanoscale analytical techniques and their use in the measurement of neurotransmitters and hormones. His goals include observing these measurements both in vivo and in single cells. Dr. Kennedy’s research in the dynamics of extracellular signaling molecules is being applied to fundamental studies of G-proteins, proteins with SH2 domains, and phosphorylated proteins. Much of this research applies to the field of brain neurochemistry and the role of these molecules in a wide variety of mental disorders. Dr. Kennedy received his Ph.D. in Chemistry from the University of North Carolina, Chapel Hill and has received a number of society and industry awards for innovation and creativity in Analytical Chemistry.

Jeanne Loring, Ph.D., Adjunct Assoc. Professor, The Burnham Institute
Dr. Loring’s primary research interests are in drug discovery in human embryonic stem cells, gene expression profiling (microarray) to characterize models of human disease and discovery of novel therapies for Alzheimer’s disease. Dr. Loring generated nine of the approximately 60 human embryonic stem cell derivations that were recognized in 2001 by the NIH as eligible for federal funding. Dr. Loring joined the faculty of Burnham Institute as a principal investigator in 2004. Prior to the Burnham, Dr. Loring held positions in senior research management at several biotech companies including Incyte Genomics and GenPharm International as well as a past faculty position in Embryology at the University of California at Davis. Dr. Loring holds a bachelor’s degree in Molecular Biology (magna cum laude) from the University of Washington and a Ph.D. in Developmental Neurobiology from the University of Oregon. Dr. Loring also serves on the scientific review boards of the NIH Brain Disorders/Clinical Neurosciences Study Section and the scientific advisory council of the Alzheimer’s Association.

Bishr Omary, Ph.D., M.D. Professor of Gastroenterology & Hepatology, Stanford University School of Medicine
Dr. Omary’s research interests include studying disease-related, cell biological and molecular aspects of cytoskeletal and other proteins in digestive organs. Dr. Omary is applying his research to the understanding of inflammatory bowel diseases and Barrett’s esophagus. Other clinical interests include crytogenic cirrhosis, colonic cancer and polyps. Recently, Dr. Omary’s Lab identified keratin mutations as a major predisposition to the development of liver cirrhosis. Dr. Omary has collaborated with Cell Biosciences in these studies on an early-phase, single-cell analysis instrument. Dr. Omary received his Ph.D. in Cell Biology/Immunology from UCSD and completed a Ph.D. to M.D. program at the University of Miami. After a medical residency at the University of California, Irvine, Dr. Omary served a fellowship at UCSD and joined the Stanford faculty in 1989 with a lab at the Veteran’s Administration Hospital. At Stanford, Dr. Omary has served as chief of Gastroenterology and Hepatology and director of the Digestive Disease Center.

---